Research and
education
deserve attention.

Which is just
what we create.

Client's-News

15. October 2018

Donor Organs on Demand: Research Looks at Lifelike Organ Models Produced on 3D Printers:

A research project recently initiated at Karl Landsteiner University of Health Sciences aims to produce organ models with realistic material properties. These biological replicas will mainly be deployed in research and medical training, which will help to reduce the use of valuable donor organs and enable physicians to practise complex surgical procedures.

read more

Client's-News

28. September 2018

COCA-COLA tastes the feeling in Vienna:

In order to balance the energy resources of its staff, CCB Management Services GmbH (a subsidiary of Coca-Cola Hellenic Bottling Company) and the Austrian company, XuendR, have joined forces and are now implementing a holistic, individualized fitness program. The goal of this joint effort is clear and is focused on the individual: a sustainable improvement to quality of life.

read more

 
Latest news from Facebook Facebook

PR MIT LEBERBLUT

Meist geben wir in unserer Arbeit Herzblut für unsere Kunden – doch das Ludwig Boltzmann Institut für experimentelle und klinische Traumatologie forderte mehr:

Leberblut wurde als Demonstration für Journalisten gebraucht.

Die hat es gefreut - und a bissl gegraust.
... See MoreSee Less

PR MIT LEBERBLUT

Meist geben wir in unserer Arbeit Herzblut für unsere Kunden – doch das Ludwig Boltzmann Institut für experimentelle und klinische Traumatologie forderte mehr:

Leberblut wurde als Demonstration für Journalisten gebraucht.

Die hat es gefreut - und a bissl gegraust.
Upcoming Events

AM PULS Nr. 62

The Food of the Future –

From the Retort to the Worm

 

(in German only)

 

ap-schriftzug

Thursday, 22th November 2018 • 6 pm

Kunden-News

28. September 2018

COCA-COLA tastes the feeling in Vienna:

In order to balance the energy resources of its staff, CCB Management Services GmbH (a subsidiary of Coca-Cola Hellenic Bottling Company) and the Austrian company, XuendR, have joined forces and are now implementing a holistic, individualized fitness program. The goal of this joint effort is clear and is focused on the individual: a sustainable improvement to quality of life.

News lesen

Kunden-News

29. August 2018

Vienna-based biotech company Marinomed on a growth path:

Vienna-based Marinomed Biotech AG (Marinomed) continues its growth path. The company is making significant progress in developing its Marinosolv® technology platform and can start a Phase III clinical approval study for the first product derived from the technology platform earlier than expected, still in winter 2018/19. For its established Carragelose® platform, which comprises innovative patent-protected products for the treatment of viral infections of the respiratory tract, the biopharmaceutical company was able to expand its sales territory by ten markets with the conclusion of two new contracts.

News lesen

Kunden-News

28. August 2018

Viruses Against Bacteria: Development of Novel Therapeutics Boosted With Millions of Euros:

The development of alternative therapies to combat antibiotic-resistant bacteria has attracted more than €4 million in grants and private investments for Vienna-based biotech company PhagoMed Biopharma GmbH (PhagoMed). PhagoMed, located at the Vienna Biocenter, is focused on developing virus–(phage–) based therapies against bacterial infections. The financing will be used to continue the pre-clinical development of three drug candidates.

News lesen

Kunden-News

9. August 2018

On the “shelf life” of water: Hot on the trail of the biostability of water using state-of-the-art DNA and cell analysis:

In order to better understand and assess the quality of ground and spring water, state-of-the-art methods from the fields of molecular biology and microbiology, as well as chemical high-performance analytics are now developed. This has been made possible by a project currently underway at the Karl Landsteiner University of Health Sciences (KL Krems).

News lesen

Kunden-News

7. August 2018

Vienna-based biotech company Marinomed obtains EU-wide certification for new cold medication:

Vienna-based company Marinomed Biotech AG (Marinomed) today announced it had secured EU-wide certification for a new product: a nasal spray that allows the decongestion of the nasal cavity without employing a pharmaceutical ingredient and tackles viral infections of the airways at the same time. The groundbreaking combination is based on a formulation for which Marinomed has submitted a patent application.

News lesen

Kunden-News

31. July 2018

Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team – Company reports strong growth.:

Vienna based Marinomed Biotech AG (Marinomed) strengthens its management team with the appointment of Pascal Schmidt as Chief Financial Officer (CFO) from  August 1, 2018. This addition to the leadership team marks another important milestone in the further growth trajectory of the biopharmaceutical firm which develops innovative technology platforms.

News lesen

Kunden-News

18. July 2018

Biotech Company Marinomed Successfully Tests New Combination Drug Against Viral Respiratory Tract Infection:

Carragelose®, a broadly effective compound for treating cold viruses, can be combined with Xylometazoline, a compound that reduces inflammation in the nasal mucosa without sacrificing efficacy. This is reflected in the findings of an in vitro study which will form the basis for developing a single drug that combats viral infections as well as freeing up blocked airways. The study was carried out by Vienna-based biotech company Marinomed Biotech AG (Marinomed) and the results have now been published in an international journal.

News lesen